84315-25-3

Basic information

• Product Name: 5,7-Difluoro-2,3-dihydroinden-1-one
• Synonyms: 5,7-Difluoro-1-indanone;5,7-Difluoro-2,3-dihydroinden-1-one;5,7-Difluoro-2,3-dihydro-1H-inden-1-one;1H-Inden-1-one, 5,7-difluoro-2,3-dihydro-;5,7-Difluoro-2,3-dihydro-1H-indene-1-one;5,7-Difluoroindan-1-one
• CAS NO: 84315-25-3
• Molecular Formula: C9H6F2O
• Molecular Weight: 168.14
• Product Categories: Aryl Fluorinated Building Blocks;Building Blocks;C8-C12;C9;Carbonyl Compounds;Chemical Synthesis;Fluorinated Building Blocks;Ketones;Organic Building Blocks;Organic Fluorinated Building Blocks;Other Fluorinated Organic Building Blocks
• Mol File: 84315-25-3.mol
• Article Data: 8

Chemical Properties

• Melting Point: 80-84 °C
• Boiling Point: 251.96 °C at 760 mmHg
• Flash Point: 95.924 °C
• Appearance: /
• Density: 1.362 g/cm³
• Vapor Pressure: 0.02mmHg at 25°C
• Refractive Index: 1.537
• Storage Temp.: 2-8°C
• Water Solubility: Sparingly soluble in water 0.081 g/L 25°C.
• CAS DataBase Reference: 5,7-Difluoro-2,3-dihydroinden-1-one(CAS DataBase Reference)
• NIST Chemistry Reference: 5,7-Difluoro-2,3-dihydroinden-1-one(84315-25-3)
• EPA Substance Registry System: 5,7-Difluoro-2,3-dihydroinden-1-one(84315-25-3)

Safety Data

• Hazard Codes: Xn
• Statements: 20/21/22-36/37/38-52/53
• Safety Statements: 26-36/37-61
• WGK Germany: 3
• Hazardous Substances Data: 84315-25-3(Hazardous Substances Data)

Usage

Uses

5,7-Difluoro-1-indanone is used as pharmaceutical intermediate.

InChI:InChI=1/C9H6F2O/c10-6-3-5-1-2-8(12)9(5)7(11)4-6/h3-4H,1-2H2

Upstream product

• 461-96-1 3,5-difluorobromobenzene 
• 32085-88-4 3,5-difluorobenzaldehyde 
• 923977-12-2 5-(3,5-difluoro-benzyl)-2,2-dimethyl-[1,3]dioxane-4,6-dione 
• 95333-92-9 3-(3,5-difluorophenyl)propionyl chloride 
• 84315-24-2 3-(3,5-difluorophenyl)propionic acid 
• 84315-23-1 3,5-difluorocinnamic acid 

Downstream Products

• 1595028-22-0 8-(4-methoxyphenyl)-6-(3,6,6-trimethyl-4-oxo-4,5,6,7-tetrahydro-1H-indol-1-yl)-3,4-dihydroisoquinolin-1(2H)-one 
• 1595028-20-8 8-(3-fluorophenyl)-6-(3,6,6-trimethyl-4-oxo-4,5,6,7-tetrahydro-1H-indol-1-yl)-3,4-dihydroisoquinolin-1(2H)-one 
• 1595028-18-4 8-(4-fluorophenyl)-6-(3,6,6-trimethyl-4-oxo-4,5,6,7-tetrahydro-1H-indol-1-yl)-3,4-dihydroisoquinolin-1(2H)-one 
• 1595028-16-2 8-phenyl-6-(3,6,6-trimethyl-4-oxo-4,5,6,7-tetrahydro-1H-indol-1-yl)-3,4-dihydroisoquinolin-1(2H)-one 
• 1595028-14-0 8-benzyl-6-(3,6,6-trimethyl-4-oxo-4,5,6,7-tetrahydro-1H-indol-1-yl)-3,4-dihydroisoquinolin-1(2H)-one 
• 1595028-04-8 8-cyclohexyl-6-(3,6,6-trimethyl-4-oxo-4,5,6,7-tetrahydro-1H-indol-1-yl)-3,4-dihydroisoquinolin-1(2H)-one 

Relevant articles and documents

Synthetic method of 7-fluoro-5-hydroxy-2,3-dihydro-1hydrogen-indene-1-one

The invention relates to a synthetic method of 7-fluoro-5-hydroxy-2,3-dihydro-1hydrogen-indene-1-one. The technical problem that there is no synthetic method suitable for industrialization at present is mainly solved. The synthetic method of the invention

Efficient synthesis of halo indanones via chlorosulfonic acid mediated Friedel-Crafts cyclization of aryl propionic acids and their use in alkylation reactions

Several halo indanones were synthesized from benzyl Meldrum's acid derivatives in two steps. Although several Lewis acids are effective for the Friedel-Crafts ring-closing reaction on more electron-rich arenes, in the case of the electron-deficient arenes this chemistry is not efficient. Here it is reported that chlorosulfonic acid (used as solvent) is an efficient reagent for cyclization of electron-withdrawing arenes. These molecules are potentially useful for subsequent alkylation reactions. The selective alkylation of 5,7-dibromo indanone is demonstrated using Pd-catalyzed Grignard coupling to provide monoalkylated indanone in good yield.

4-SUBSTITUTED IMIDAZOLE-2-THIONES AND IMIDAZOL- 2-ONES AS AGONISTS OF THE ALPHA- 2B AND ALPHA-2C ADRENERGIC RECEPTORS

Compounds of Formula (I): where X is S and the variables have the meaning defined in the specification are specific or selective to alpha2B and/or alpha2C adrenergic receptors in preference over alpha2A adrenergic receptors, and as such have no or only minimal cardivascular and/or sedatory activity. These compounds of Formula (I) are useful as medicaments in mammals, including humans, for treatment of diseases and or alleviations of conditions which are responsive to treatment by agonists of alpha2B adrenergic receptors. Compounds of Formula (I) where X is O also have the advantageous property that they have no or only minimal cardivascular and/or sedatory activity and are useful for treating pain and other conditions with no or only minimal cardivascular and/or sedatory activity.